Compare SPB & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPB | MESO |
|---|---|---|
| Founded | 1906 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 1994 | 2005 |
| Metric | SPB | MESO |
|---|---|---|
| Price | $86.98 | $17.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $82.40 | N/A |
| AVG Volume (30 Days) | ★ 369.4K | 175.2K |
| Earning Date | 05-07-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $3,802,100,000.00 | N/A |
| Revenue This Year | $2.03 | $629.74 |
| Revenue Next Year | $1.85 | $30.65 |
| P/E Ratio | $85.31 | ★ N/A |
| Revenue Growth | ★ 20.86 | N/A |
| 52 Week Low | $49.99 | $12.66 |
| 52 Week High | $99.06 | $21.50 |
| Indicator | SPB | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 57.18 |
| Support Level | $85.81 | $16.67 |
| Resistance Level | $90.60 | $17.10 |
| Average True Range (ATR) | 3.07 | 0.36 |
| MACD | -0.48 | 0.13 |
| Stochastic Oscillator | 11.16 | 69.39 |
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, which generates maximum revenue; Global Pet Care; and Home and Garden. The company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific. It generates maximum revenue from North America.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.